← Stocks · TVRD record
Signal record & history · Trifecta Signals
Tvardi has been flagged by the Trifecta screener 3 times since 2022. 3 signals confirmed; the median confirmed signal is down 99.6% since its Early Signal.
Price refreshes every trading day after the close.
Full interactive chart ↗ · partner link
Daily closes · through the most recent close
Price history from Jan 2018 · Signal tracking began Jan 2022
Headline statistics: confirmed signals only, measured from the confirmation price.
First signal May 2022 · Latest Jul 2023 · Confirmed 3 of 3 Early · Latest close in the chart data: Wed, Nov 4, 2026
Groups are mutually exclusive — every confirmed signal sits in exactly one.
Since May 2022, Tvardi has had three Early signals, three confirmed. Two of the three decided signals gained +10% within 90 days, and zero of three finished ahead of the S&P 500 since confirmation. Three signals carried a caution flag.
Every Early signal in the record, newest first.
Members see every signal below, and the group mix above.
Membership unlocks the complete signal timeline for TVRD and every other stock in the record — group tags, caution flags, and the full screener.
Already a member? Sign in and this page unlocks.
Tvardi Therapeutics sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Its market value of about $11 million places it in the small-cap group.
The strongest run on Tvardi Therapeutics’ record followed a confirmation in May 2022, gaining about 31% over the following 90 days. Another example came in March 2023, when a signal landed in the Downtrend group and the shares fell about 34% over the next 90 days. For classification, its latest signal was rated Low Quality, revenue was growing by about 67% at the time, and it sat in the mid-cap group when that signal fired.
At the most recent close, Wednesday, November 4, the shares finished at $0.86, up 3.2% on the day. The last five sessions span about $0.79 to about $0.86.
